Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Molecular Cancer Therapeutics|January 16, 2015
CD30 is a potential therapeutic target in malignant mesotheliomaSnehal Dabir, Adam Kresak, Michael Yang, et al.
Molecular Oncology|September 28, 2018
Post-transcriptional regulation of PIAS3 expression by miR-18a in malignant mesotheliomaTian He, Karen McColl, Nneha Sakre, et al.
British Journal of Cancer|December 1, 2020
CBL0137 increases the targeting efficacy of Rovalpituzumab tesirine against tumour-initiating cells in small cell lung cancerDaniel J Lindner, Gary Wildey, Yvonne Parker, et al.
Oncotarget|November 19, 2016
RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTORNneha Sakre, Gary Wildey, Mohadese Behtaj, et al.
Plos One|September 9, 2014
Pharmacogenomic approach to identify drug sensitivity in small-cell lung cancerGary Wildey, Yanwen Chen, Ian Lent, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2014
Low PIAS3 expression in malignant mesothelioma is associated with increased STAT3 activation and poor patient survivalSnehal Dabir, Amy Kluge, Adam Kresak, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 24, 2016
Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance)Arnaud Augert, Qing Zhang, Breanna Bates, et al.
International Journal of Cancer|August 21, 2013
PIAS3 activates the intrinsic apoptotic pathway in non-small cell lung cancer cells independent of p53 statusSnehal Dabir, Amy Kluge, Karen McColl, et al.
Cancer Medicine|January 10, 2015
PIAS3 expression in squamous cell lung cancer is low and predicts overall survivalRime Abbas, Karen S McColl, Adam Kresak, et al.
Pageof 2